Page last updated: 2024-08-23

pirfenidone and Pneumonia

pirfenidone has been researched along with Pneumonia in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's5 (38.46)24.3611
2020's7 (53.85)2.80

Authors

AuthorsStudies
Bo, C; Jia, Q; Li, M; Tang, Q; Xing, C; Zhang, Z1
Abdelmoneim, AM; Alanazi, MM; Baioumy, B; El-Shafey, RS; Elshazly, AME; Faruk, EM; Hussein, AYA; Mersal, EA; Mogahed, MM; Morsi, AA1
Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO1
Ali, MF; Anderson, DK; Aubry, MC; Carmona, EM; Dasari, H; Egan, AM; Kottom, TJ; Limper, AH; Peikert, T; Shaughnessy, GF; Van Keulen, VP; Yi, ES1
Cheng, X; Han, X; Li, J; Yu, H; Yu, L; Zhang, X1
Miao, K; Tian, X; Xu, W; Xu, Y; Zhang, L; Zhang, Y1
Cao, ZJ; Dai, HP; Han, ZF; Li, BC; Li, ZG; Liu, Y; Pang, JL; Qi, XM; Song, MY; Wang, C; Wang, J; Yang, PR; Zhang, XR; Zhang, Z1
Ghazi-Khansari, M; Heidari, MR; Iranpour, M; Mandegary, A; Pourgholamhossein, F; Pourgholi, L; Pournamdari, M; Poursalehi, HR; Rasooli, R; Samareh-Fekri, M1
Dai, M; Hu, C; Hu, Y; Li, H; Li, Q; Li, Y; Liu, S; Long, Y; Mao, Z; Pan, P; Song, C; Su, X; Tan, H; Wu, D; Zhang, L1
Aoki, Y; Kato, M; Kojo, Y; Onoue, S; Seto, Y; Yamada, S1
Aebischer, O; Benmachiche, M; Bonjour, T; Carrel, G; Castioni, J; Cosma-Rochat, M; Fournier, J; Gachoud, D; Gagliano, M; Giger, A; Greiser, J; Lamy, O; Méan, M; Mieville, A; Rouiller Larpin, N; Tusgul, S; Voruz, S; Wenger, N1
Chan, HK; Leung, SS; Onoue, S; Seto, Y; Suzuki, G1
Case, N; Chapman, RW; Crawley, Y; Egan, RW; Fine, J; Hey, JA; Kreutner, W; Kung, T; Minnicozzi, M; Spond, J; Wang, P1

Reviews

1 review(s) available for pirfenidone and Pneumonia

ArticleYear
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021, Jul-20, Volume: 24, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Male; Nivolumab; Pneumonia; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridones; Quinolines; Retrospective Studies

2021

Trials

1 trial(s) available for pirfenidone and Pneumonia

ArticleYear
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
    Respiratory medicine, 2023, Volume: 217

    Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones

2023

Other Studies

11 other study(ies) available for pirfenidone and Pneumonia

ArticleYear
Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways.
    Ecotoxicology and environmental safety, 2022, Oct-01, Volume: 244

    Topics: Animals; Fibrosis; Hydroxyproline; Interleukin-18; Janus Kinase 2; Macrophages; Pneumonia; Pulmonary Fibrosis; Pyridones; Rats; RNA, Messenger; Signal Transduction; Silicosis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vimentin

2022
Modeling the Effects of Cypermethrin Toxicity on Ovalbumin-Induced Allergic Pneumonitis Rats: Macrophage Phenotype Differentiation and p38/STAT6 Signaling Are Candidate Targets of Pirfenidone Treatment.
    Cells, 2023, 03-24, Volume: 12, Issue:7

    Topics: Alveolitis, Extrinsic Allergic; Animals; Asthma; Dexamethasone; Inflammation; Macrophages; Male; Ovalbumin; p38 Mitogen-Activated Protein Kinases; Phenotype; Pneumonia; Rats; Rats, Wistar

2023
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.
    American journal of respiratory cell and molecular biology, 2021, Volume: 64, Issue:6

    Topics: Antigens; B-Lymphocytes; Cell Aggregation; Cell Movement; Cell Proliferation; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Inflammation Mediators; Interleukin-6; Pneumonia; Pyridones; src-Family Kinases; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2021
Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
    Thoracic cancer, 2021, Volume: 12, Issue:15

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Male; Pneumonia; Pyridones

2021
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A.
    Acta pharmacologica Sinica, 2022, Volume: 43, Issue:4

    Topics: Animals; Disease Models, Animal; Fibrosis; Inflammation; Interleukin-17; Janus Kinases; Lung; Mice; Mice, Inbred C57BL; Pneumonia; Pyridones; Signal Transduction; Silicon Dioxide; STAT Transcription Factors

2022
Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2018, Volume: 112

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bronchoalveolar Lavage Fluid; Fibrosis; Gene Expression; Gene Expression Profiling; Herbicides; Hydroxyproline; Lung; Lung Injury; Male; Mice; Organ Size; Oxidative Stress; Paraquat; Pneumonia; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1

2018
Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
    Molecular immunology, 2018, Volume: 99

    Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Caspase 1; Cell Line; Fibrosis; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1

2018
Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
    Pharmaceutical research, 2013, Volume: 30, Issue:6

    Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Dermatitis, Phototoxic; Lung; Male; Pharmaceutical Solutions; Pneumonia; Powders; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley

2013
[What is new in 2014 for the specialist in hospital internal medicine? The point of view of university hospital chief residents].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arterial Pressure; Catheterization, Central Venous; Diverticulitis; Emergency Service, Hospital; Hospitals, University; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Internal Medicine; Kidney; Medical Staff, Hospital; Pneumonia; Pulmonary Embolism; Pyridones; Shock, Septic; Sympathectomy; Tumor Necrosis Factor-alpha; Ultrasonography; Venous Thromboembolism; Vitamin B 12 Deficiency; Vitamin E

2015
Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.
    Pharmaceutical research, 2016, Volume: 33, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Chromatography, Liquid; Desiccation; Disease Models, Animal; Drug Compounding; Male; Ovalbumin; Particle Size; Peroxidase; Pneumonia; Powders; Pyridones; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Technology, Pharmaceutical

2016
Inhibition of experimental acute pulmonary inflammation by pirfenidone.
    Pulmonary pharmacology & therapeutics, 2003, Volume: 16, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Guinea Pigs; Humans; Interleukin-6; Lipopolysaccharides; Male; Mice; Pneumonia; Pulmonary Disease, Chronic Obstructive; Pyridones; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha

2003